Top

Published in:

01-12-2012 | Meta-Analysis

The association between metabolic syndrome and bone mineral density: a meta-analysis

Authors: Peng Xue, Ping Gao, Yukun Li

Published in: Endocrine | Issue 3/2012

Abstract

Previous researches demonstrate uncertainty about the effect of metabolic syndrome (MS) on bone. We performed a meta-analysis to investigate the association of MS with bone mineral density (BMD) of spine and femoral neck (FN). In this meta-analysis, searches of Medline, Embase, Cochrane Library, Chinese biological medical database and China national knowledge infrastructure were undertaken to identify studies in humans of the association between MS and BMD. Random effects model was used for this meta-analysis. The results of our research were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A total of 11 studies (including an outlier study) with 13,122 subjects were included in our research. We detected a significant overall association of MS with increased BMD of spine (weighted mean difference, WMD = 0.027, 95 % confidence interval, CI [0.011, 0.042]) and no significant overall association of MS with BMD of FN (WMD = 0.008, CI [−0.011, 0.026]). Subgroup analyses indicated significant association between MS and increased BMD of spine in subjects whose BMD was measured by dual-energy X-ray absorptiometry (DXA) scanner manufactured by Hologic Inc., subjects diagnosed by International Diabetes Federation criteria and subjects diagnosed by National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATP III) criteria. And significant association between MS and increased BMD of FN in Caucasian subjects, subjects whose BMD was measured by DXA scanner manufactured by Hologic Inc. and subjects diagnosed by NCEP-ATP III criteria was also found. Our meta-analysis suggests that MS has no clear influence on BMD, or its influence maybe beneficial.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6), 785–795 (2001)

Writing Group for the ISCD Position Development Conference, Diagnosis of osteoporosis in men, premenopausal women, and children. J. Clin. Densitom. 7(1), 17–26 (2004)

J.Y. Reginster, P. Gillet, W. Ben Sedrine, G. Brands, O. Ethgen, C. de Froidmont, C. Gosset, Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 15(5), 507–514 (1999)PubMedCrossRef

C. Gazzaruso, An increased risk for fractures: another cause of frailty in HIV-infected subjects. Endocrine (2012). doi:10.1007/s12020-012-9640-0

M.A. Cornier, D. Dabelea, T.L. Hernandez, R.C. Lindstrom, A.J. Steig, N.R. Stob, R.E. Van Pelt, H. Wang, R.H. Eckel, The metabolic syndrome. Endocr. Rev. 29(7), 777–822 (2008). doi:10.1210/er.2008-0024 PubMedCrossRef

A.S. Gami, B.J. Witt, D.E. Howard, P.J. Erwin, L.A. Gami, V.K. Somers, V.M. Montori, Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49(4), 403–414 (2007). doi:10.1016/j.jacc.2006.09.032 PubMedCrossRef

E.S. Ford, C. Li, N. Sattar, Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 31(9), 1898–1904 (2008). doi:10.2337/dc08-0423 PubMedCrossRef

L.R. Nelson, S.E. Bulun, Estrogen production and action. J. Am. Acad. Dermatol. 45(3 Suppl), S116–S124 (2001)PubMedCrossRef

H. Ohta, T. Ikeda, T. Masuzawa, K. Makita, Y. Suda, S. Nozawa, Differences in axial bone mineral density, serum levels of sex steroids, and bone metabolism between postmenopausal and age- and body size-matched premenopausal subjects. Bone 14(2), 111–116 (1993)PubMedCrossRef

10.

L.C. Hofbauer, M. Schoppet, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292(4), 490–495 (2004). doi:10.1001/jama.292.4.490 PubMedCrossRef

11.

B.J. Smith, M.R. Lerner, S.Y. Bu, E.A. Lucas, J.S. Hanas, S.A. Lightfoot, R.G. Postier, M.S. Bronze, D.J. Brackett, Systemic bone loss and induction of coronary vessel disease in a rat model of chronic inflammation. Bone 38(3), 378–386 (2006). doi:10.1016/j.bone.2005.09.008 PubMedCrossRef

12.

R.M. Campos, A. de Piano, P.L. da Silva, J. Carnier, P.L. Sanches, F.C. Corgosinho, D.C. Masquio, M. Lazaretti-Castro, L.M. Oyama, C.M. Nascimento, L. Tock, M.T. de Mello, S. Tufik, A.R. Damaso, The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine (2012). doi:10.1007/s12020-012-9613-3 PubMed

13.

S. Cvijetic, M. Pavlovic, D. Pasalic, S. Dodig, Ultrasound bone measurement in an older population with metabolic syndrome. Aging Clin Exp Res 23(1), 29–34 (2011)PubMed

14.

D.N. Binici, N. Gunes, Risk factors leading to reduced bone mineral density in hemodialysis patients with metabolic syndrome. Ren. Fail. 32(4), 469–474 (2010). doi:10.3109/08860221003675260 PubMedCrossRef

15.

M. Kinjo, S. Setoguchi, D.H. Solomon, Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U.S. sample. J. Clin. Endocrinol. Metab. 92(11), 4161–4164 (2007). doi:10.1210/jc.2007-0757 PubMedCrossRef

16.

Y.H. Tseng, K.C. Huang, M.L. Liu, W.T. Shu, W.H. Sheu, Association between metabolic syndrome (MS) and bone mineral loss: a cross-sectional study in Puli Township in Taiwan. Arch. Gerontol. Geriatr. 49(Suppl 2), S37–S40 (2009). doi:10.1016/S0167-4943(09)70011-1 PubMedCrossRef

17.

T. Yamaguchi, I. Kanazawa, M. Yamamoto, S. Kurioka, M. Yamauchi, S. Yano, T. Sugimoto, Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone 45(2), 174–179 (2009). doi:10.1016/j.bone.2009.05.003 PubMedCrossRef

18.

L.A. Ahmed, H. Schirmer, G.K. Berntsen, V. Fonnebo, R.M. Joakimsen, Features of the metabolic syndrome and the risk of non-vertebral fractures: the Tromso study. Osteoporos. Int. 17(3), 426–432 (2006). doi:10.1007/s00198-005-0003-z PubMedCrossRef

19.

G. Iacobellis, M. Iorio, N. Napoli, D. Cotesta, L. Zinnamosca, C. Marinelli, L. Petramala, S. Minisola, E. D’Erasmo, C. Letizia, Relation of adiponectin, visfatin and bone mineral density in patients with metabolic syndrome. J. Endocrinol. Investig. 34(1), e12–e15 (2011). doi:10.3275/7170

20.

H.T. Lee, J. Shin, Y.H. Lim, B.K. Kim, Y.T. Kim, J.U. Lee, S. Hong, S.Y. Song, S.H. Cho, The relationship between coronary artery calcification and bone mineral density in patients according to their metabolic syndrome status. Korean Circ. J. 41(2), 76–82 (2011). doi:10.4070/kcj.2011.41.2.76 PubMedCrossRef

21.

L.J. Lu, F. Nayeem, K.E. Anderson, J.J. Grady, M. Nagamani, Lean body mass, not estrogen or progesterone, predicts peak bone mineral density in premenopausal women. J. Nutr. 139(2), 250–256 (2009). doi:10.3945/jn.108.098954 PubMed

22.

J. Lidfeldt, L. Holmdahl, G. Samsioe, C. Nerbrand, P. Nyberg, B. Schersten, C.D. Agardh, The influence of hormonal status and features of the metabolic syndrome on bone density: a population-based study of Swedish women aged 50 to 59 years. The women’s health in the Lund area study. Metabolism 51(2), 267–270 (2002)PubMedCrossRef

23.

Y.K. Jeon, J.G. Lee, S.S. Kim, B.H. Kim, S.J. Kim, Y.K. Kim, I.J. Kim, Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. Endocr. J. 58(2), 87–93 (2011)PubMedCrossRef

24.

P. Szulc, A. Varennes, P.D. Delmas, J. Goudable, R. Chapurlat, Men with metabolic syndrome have lower bone mineral density but lower fracture risk—the MINOS study. J. Bone Miner. Res. 25(6), 1446–1454 (2010). doi:10.1002/jbmr.13 PubMedCrossRef

25.

K.K. Park, S.J. Kim, E.S. Moon, Association between bone mineral density and metabolic syndrome in postmenopausal Korean women. Gynecol. Obstet. Investig. 69(3), 145–152 (2010). doi:10.1159/000264665 CrossRef

26.

D. von Muhlen, S. Safii, S.K. Jassal, J. Svartberg, E. Barrett-Connor, Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo study. Osteoporos. Int. 18(10), 1337–1344 (2007). doi:10.1007/s00198-007-0385-1 CrossRef

27.

D.K. Hwang, H.J. Choi, The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos. Int. 21(3), 425–431 (2010). doi:10.1007/s00198-009-0990-2 PubMedCrossRef

28.

M. Boyanov, D. Bakalov, Z. Boneva, Bone mineral density in men with and without the metabolic syndrome. Aging Male 12(2–3), 62–65 (2009). doi:10.1080/13685530903150812 PubMedCrossRef

29.

J.L. Hernandez, J.M. Olmos, E. Pariente, J. Martinez, C. Valero, P. Garcia-Velasco, D. Nan, J. Llorca, J. Gonzalez-Macias, Metabolic syndrome and bone metabolism: the Camargo Cohort study. Menopause 17(5), 955–961 (2010). doi:10.1097/gme.0b013e3181e39a15 PubMedCrossRef

30.

S. Yaturu, S. Humphrey, C. Landry, S.K. Jain, Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes. Med. Sci. Monit. 15(1), CR5–CR9 (2009)PubMed

31.

H.Y. Kim, J.W. Choe, H.K. Kim, S.J. Bae, B.J. Kim, S.H. Lee, J.M. Koh, K.O. Han, H.M. Park, G.S. Kim, Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. Calcif. Tissue Int. 86(5), 350–358 (2010). doi:10.1007/s00223-010-9347-2 PubMedCrossRef

32.

Y.-J. Zhang, W. Zhao, H. Zhang, X.-M. Wu, L.-J. Jiang, X.-C. Song, M. Li, Effect of metabolic syndrome on bone mineral density of male patients with type 2 diabetes. TianJin Med. J. 38(3), 230–232 (2010)

33.

Y.-J. Zhang, W. Zhao, H. Zhang, J. Liu, X.-Q. Chen, S.-S. Cui, L. Zhang, Analysis of the related factors of bone mineral density in female patients with type 2 diabetes complicated metabolic syndrome. Chin. J. Prev. Control Chronic Dis. 18(05), 481–482 (2010)

34.

D.T. Felson, Y. Zhang, M.T. Hannan, J.J. Anderson, Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J. Bone Miner. Res. 8(5), 567–573 (1993). doi:10.1002/jbmr.5650080507 PubMedCrossRef

35.

R. Marcus, G. Greendale, B.A. Blunt, T.L. Bush, S. Sherman, R. Sherwin, H. Wahner, B. Wells, Correlates of bone mineral density in the postmenopausal estrogen/progestin interventions trial. J. Bone Miner. Res. 9(9), 1467–1476 (1994). doi:10.1002/jbmr.5650090920 PubMedCrossRef

36.

C. De Laet, J.A. Kanis, A. Oden, H. Johanson, O. Johnell, P. Delmas, J.A. Eisman, H. Kroger, S. Fujiwara, P. Garnero, E.V. McCloskey, D. Mellstrom, L.J. Melton III, P.J. Meunier, H.A. Pols, J. Reeve, A. Silman, A. Tenenhouse, Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos. Int. 16(11), 1330–1338 (2005). doi:10.1007/s00198-005-1863-y PubMedCrossRef

37.

J.M. Gimble, M.E. Nuttall, Bone and fat: old questions, new insights. Endocrine 23(2–3), 183–188 (2004). doi:10.1385/ENDO:23:2-3:183 PubMedCrossRef

38.

S.L. Edelstein, E. Barrett-Connor, Relation between body size and bone mineral density in elderly men and women. Am. J. Epidemiol. 138(3), 160–169 (1993)PubMed

39.

E.A. Jankowska, E. Rogucka, M. Medras, Are general obesity and visceral adiposity in men linked to reduced bone mineral content resulting from normal ageing? A population-based study. Andrologia 33(6), 384–389 (2001)PubMedCrossRef

40.

R. Blaauw, E.C. Albertse, S. Hough, Body fat distribution as a risk factor for osteoporosis. S. Afr. Med. J. 86(9), 1081–1084 (1996)PubMed

41.

C. Torti, G. Mazziotti, P.A. Soldini, E. Foca, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine (2011). doi:10.1007/s12020-011-9586-7 PubMed

42.

S.S. Moon, Y.S. Lee, S.W. Kim, Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine (2012). doi:10.1007/s12020-012-9639-6 PubMed

43.

A.H. Holmberg, P.M. Nilsson, J.A. Nilsson, K. Akesson, The association between hyperglycemia and fracture risk in middle age. A prospective, population-based study of 22,444 men and 10,902 women. J. Clin. Endocrinol. Metab. 93(3), 815–822 (2008). doi:10.1210/jc.2007-0843 PubMedCrossRef

44.

I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Yano, T. Sugimoto, Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men. Calcif. Tissue Int. 83(5), 324–331 (2008). doi:10.1007/s00223-008-9178-6 PubMedCrossRef

45.

K. Agbaht, A. Gurlek, J. Karakaya, M. Bayraktar, Circulating adiponectin represents a biomarker of the association between adiposity and bone mineral density. Endocrine 35(3), 371–379 (2009). doi:10.1007/s12020-009-9158-2 PubMedCrossRef

46.

G. Mazziotti, M. Gola, A. Bianchi, T. Porcelli, A. Giampietro, V. Cimino, M. Doga, C. Gazzaruso, L. De Marinis, A. Giustina, Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40(1), 102–108 (2011). doi:10.1007/s12020-011-9486-x PubMedCrossRef

47.

D.E. Grobbee, W.H. Hackeng, J.C. Birkenhager, A. Hofman, Raised plasma intact parathyroid hormone concentrations in young people with mildly raised blood pressure. Br. Med. J. (Clin. Res. Ed.) 296(6625), 814–816 (1988)CrossRef

48.

G.S. Hughes Jr, M.J. Oexmann, H.S. Margolius, S. Epstein, N.H. Bell, Normal vitamin D and mineral metabolism in essential hypertension. Am. J. Med. Sci. 296(4), 252–259 (1988)PubMed

49.

D.A. Hanley, J.P. Brown, A. Tenenhouse, W.P. Olszynski, G. Ioannidis, C. Berger, J.C. Prior, L. Pickard, T.M. Murray, T. Anastassiades, S. Kirkland, C. Joyce, L. Joseph, A. Papaioannou, S.A. Jackson, S. Poliquin, J.D. Adachi, Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J. Bone Miner. Res. 18(4), 784–790 (2003). doi:10.1359/jbmr.2003.18.4.784 PubMedCrossRef

50.

M.E. Mussolino, R.F. Gillum, Bone mineral density and hypertension prevalence in postmenopausal women: results from the Third National Health and Nutrition Examination Survey. Ann. Epidemiol. 16(5), 395–399 (2006). doi:10.1016/j.annepidem.2005.06.051 PubMedCrossRef

51.

S. Xu, J.J. Yu, Beneath the minerals, a layer of round lipid particles was identified to mediate collagen calcification in compact bone formation. Biophys. J. 91(11), 4221–4229 (2006). doi:10.1529/biophysj.105.075804 PubMedCrossRef

52.

S. Adami, V. Braga, M. Zamboni, D. Gatti, M. Rossini, J. Bakri, E. Battaglia, Relationship between lipids and bone mass in 2 cohorts of healthy women and men. Calcif. Tissue Int. 74(2), 136–142 (2004). doi:10.1007/s00223-003-0050-4 PubMedCrossRef

53.

T. Yamaguchi, T. Sugimoto, S. Yano, M. Yamauchi, H. Sowa, Q. Chen, K. Chihara, Plasma lipids and osteoporosis in postmenopausal women. Endocr. J. 49(2), 211–217 (2002)PubMedCrossRef

54.

E.M. Dennison, H.E. Syddall, A. Aihie Sayer, H.J. Martin, C. Cooper, Lipid profile, obesity and bone mineral density: the Hertfordshire Cohort study. QJM 100(5), 297–303 (2007). doi:10.1093/qjmed/hcm023 PubMedCrossRef

55.

W.Y. Fujimoto, Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups. Diabet. Med. 13(9 Suppl 6), S7–S10 (1996)PubMed

56.

N. Abate, M. Chandalia, The impact of ethnicity on type 2 diabetes. J. Diabetes Complicat. 17(1), 39–58 (2003)PubMedCrossRef

57.

N.A. Pocock, K.A. Noakes, M. Griffiths, N. Bhalerao, P.N. Sambrook, J.A. Eisman, J. Freund, A comparison of longitudinal measurements in the spine and proximal femur using lunar and hologic instruments. J. Bone Miner. Res. 12(12), 2113–2118 (1997). doi:10.1359/jbmr.1997.12.12.2113 PubMedCrossRef

58.

J. Makovey, V. Naganathan, P. Sambrook, Gender differences in relationships between body composition components, their distribution and bone mineral density: a cross-sectional opposite sex twin study. Osteoporos. Int. 16(12), 1495–1505 (2005). doi:10.1007/s00198-005-1841-4 PubMedCrossRef

59.

G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012). doi:10.1007/s12020-011-9570-2 PubMedCrossRef

60.

Y. Hamada, S. Kitazawa, R. Kitazawa, K. Kono, S. Goto, H. Komaba, H. Fujii, Y. Yamamoto, H. Yamamoto, M. Usami, M. Fukagawa, The effects of the receptor for advanced glycation end products (RAGE) on bone metabolism under physiological and diabetic conditions. Endocrine 38(3), 369–376 (2010). doi:10.1007/s12020-010-9390-9 PubMedCrossRef

61.

J.A. Pasco, M.J. Henry, S. Korn, G.C. Nicholson, M.A. Kotowicz, The metabolic syndrome and bone mineral density in a random sample of Australian men. JMHG. 4(3), 298–299 (2007)

Title: The association between metabolic syndrome and bone mineral density: a meta-analysis
Authors: Peng Xue
Ping Gao
Yukun Li
Publication date: 01-12-2012
Publisher: Springer US
Published in: Endocrine / Issue 3/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9684-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome

Erratum to: Evidence of a stabilizing mutation of β-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas

Anaplastic thyroid cancer therapy: dream or reality?

Aldosterone-induced osteopontin expression in vascular smooth muscle cells involves MR, ERK, and p38 MAPK

The case against aldosterone: not proven

Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage